LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy

被引：4
|
作者：
Lee, Alexander T. J. [1 ]
Attygale, Ayoma D. [1 ]
Sharma, Rajaei K. [2 ]
Iyengar, Sunil [1 ]
El-Sharkawi, Dima [1 ]
Chau, Ian [1 ]
Vroobel, Katherine M. [1 ]
Fotiadis, Nicos [1 ]
Khan, Nasir [1 ]
Butterfield, Nicholas [1 ]
Wotherspoon, Andrew [1 ]
Cunningham, David [1 ]
Sharma, Bhupinder [1 ]
机构：
[1] Royal Marsden NHS Fdn Trust, London, England
[2] Univ Exeter, Med Sch, Exeter, Devon, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 06期
关键词：
diffuse large B cell lymphoma; polatuzumab; pseudo-progression;
D O I：
10.1111/bjh.16679
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E248 / E251
页数：4
相关论文
共 50 条
  • [41] Immune-mediated Neuropathy with Anti-disialosyl IgM Antibodies in Diffuse Large B-cell Lymphoma: A Case Report and Literature Review
    Shihashi, Gen
    Yagi, Takuya
    Suzuki, Shigeaki
    Seki, Morinobu
    Kohashi, Sumiko
    Ueda, Tomoki
    Kameyama, Kaori
    Kusunoki, Susumu
    Nakajima, Hideaki
    Okamoto, Shinichiro
    Suzuki, Norihiro
    INTERNAL MEDICINE, 2015, 54 (13) : 1647 - 1651
  • [42] Rituximab maintenance therapy in diffuse large B-cell lymphoma
    Trajkova, S.
    Panovska-Stavridis, I.
    Stojanovik, A.
    Dukovski, D.
    Cevreska, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S22 - S23
  • [43] Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
    Yu-Wen Wang
    Xavier Cheng-Hong Tsai
    Hsin-An Hou
    Feng-Ming Tien
    Jia-Hau Liu
    Wen-Chien Chou
    Bor-Sheng Ko
    Yu-Wen Chen
    Chien-Chin Lin
    Chieh-Lung Cheng
    Min-Yen Lo
    Yun-Chu Lin
    Li-Chun Lu
    Shang-Ju Wu
    Sung-Hsin Kuo
    Ruey-Long Hong
    Tai-Chung Huang
    Ming Yao
    Annals of Hematology, 2022, 101 : 349 - 358
  • [44] The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
    Lu, Tingxun
    Zhang, Jie
    Xu-Monette, Zijun Y.
    Young, Ken H.
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [45] The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
    Tingxun Lu
    Jie Zhang
    Zijun Y. Xu-Monette
    Ken H. Young
    Experimental Hematology & Oncology, 12
  • [46] Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
    Russler-Germain, David A.
    Cliff, Edward R. Scheffer
    Bartlett, Nancy L.
    BLOOD, 2023, 142 (25) : 2216 - 2219
  • [47] Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China
    Chen, Xi
    Yu, Haifeng
    Li, Cong
    Xu, Jieyu
    Lei, Tao
    Han, Shuiyun
    Peng, Shuailing
    Yang, Haiyan
    BLOOD, 2024, 144 : 7782 - 7783
  • [48] A prognostic immune risk score for diffuse large B-cell lymphoma
    Ma, Shu-Yun
    Tian, Xiao-Peng
    Cai, Jun
    Su, Ning
    Fang, Yu
    Zhang, Yu-Chen
    Wang, Jin-Ni
    Peter Gale, Robert
    Cai, Qing-Qing
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) : 111 - 119
  • [49] Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma
    Shree, Tanaya
    Li, Qian
    Glaser, Sally L.
    Brunson, Ann
    Maecker, Holden T.
    Haile, Robert W.
    Levy, Ronald
    Keegan, Theresa H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1664 - +
  • [50] US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
    Betts, Keith A.
    Thuresson, Per-Olof
    Felizzi, Federico
    Du, Ella X.
    Dieye, Ibou
    Li, Jia
    Schulz, Mathias
    Masaquel, Anthony S.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (14) : 1003 - 1015
12345